Press Releases

Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Tel Aviv, Israel — January 29, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at… Read More

Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented  Tel Aviv, Israel— January 27, 2020 – InspireMD, Inc.  (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in a live… Read More

Tel Aviv, Israel — January 6, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer,… Read More

Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer    Appointment adds significant medical technology commercialization experience to the InspireMD team   Tel Aviv, Israel — December 10, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease… Read More

Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications Tel Aviv, Israel — November 26, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention… Read More

Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET Tel Aviv, Israel— November 12, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today… Read More

Management to host conference call and webcast at 8:30am ET Tel Aviv, Israel— November 5, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on… Read More

Tel Aviv, Israel— September 19, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 2,777,777 units at a price to the public of $1.80 per unit. InspireMD expects… Read More

Tel Aviv, Israel — September 9, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update.   Positive CGuard™ EPS Data Presented at the Joint Congress of the World Heart Federation (WHF-2019) and the… Read More

Tel Aviv, Israel — September 9, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the  CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that James Barry, PhD, Chief Executive Officer and Craig Shore, Chief Financial Officer, will present a company update at the HC Wainwright… Read More